A Novel Tumor Staging System Incorporating Tumor Regression Grade (TRG) With Lymph Node Status (ypN-Category) Results in Better Prognostication Than ypTNM Stage Groups After Neoadjuvant Therapy for Esophageal Squamous Cell Carcinoma. Issue 5 (25th November 2022)

• Record Type: Journal Article
• Authors: Wong, Ian Y.H.; Chung, Jason C.Y.; Zhang, Rui Qi; Gao, X.; Lam, K.O.; Kwong, Dora L.W.; Chao, Y.K.; Law, Simon Y.K.
• Is Part Of: Annals of surgery. Volume 276:Issue 5(2022)
• Page Start: 784
• Page End: 791
• Publication Date: 2022-11-25
• Subjects: cancer staging -- esophageal cancer -- esophagectomy -- neoadjuvant therapy -- prognostic factor -- tumor regression; Surgery -- Periodicals; 617.005
• DOI: 10.1097/SLA.0000000000005636
• Languages: English
• ISSNs: 0003-4932

Abstract

Abstract : Objective: This study aims at constructing a staging system incorporating tumor regression grade and ypN-category (TRG-N) in patients with neoadjuvant therapy before esophagectomy. It is hypothesized that this would prognosticate better than the current American Joint Committee on Cancer (AJCC) postneoadjuvant therapy (ypTNM) stage groups. Background: Conventional pathological T-category is defined by the depth of invasion, and may lose prognostic relevance after neoadjuvant therapy. TRG defines treatment response by the degree of tumor regression, and when combined with ypN-category may be more prognostic than AJCC postneoadjuvant therapy (ypTNM) stage groups. Methods: A training cohort of 210 patients with esophageal squamous cell carcinoma and who had had neoadjuvant therapy before esophagectomy were studied. A validation cohort comprised 107 patients from another hospital. Resected esophagi were assessed by ypT-category and TRG, the latter assigned according to the Becker 4-tier system. These categories were grouped with ypN-category into a TRG-N system. Patients' survival was compared between the current AJCC postneoadjuvant therapy (ypTNM) stage groups and this TRG-N system. Results: In the training cohort, 5-year survival rates according to ypTNM stage I, II, IIIA, IIIB, and IVA were 53%, 39.4%, 47%, 18.3%, and 0%, respectively. For TRG-N stages I, II, III, and IV, the respective figures were 59.6%, 43.5%, 23.8%, and 15.6%. TRG-N stage showed better fit in survival than ypTNM stage groups, indicated by lower Akaike Information Criteria (AIC) and Bayesian Information Criterion values. Similar results were found in the validation cohort. Multivariate analysis showed that TRG-N stage ( P =0.02), age ( P =0.006), and sex ( P =0.005) were independent prognostic factors. Conclusion: TRG-N stage shows better prognostication than the AJCC postneoadjuvant therapy (ypTNM) stage groups.